Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone Acetonide for Desmoid Tumors
NCT03627741Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2018
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triamcinolone acetonide in desmoid tumor, sponsored by Mayo Clinic. Primary endpoints: Response rate of desmoid tumors to serial triamcinolone injections based on WHO criteria at 2 years, Response rate of desmoid tumors to serial triamcinolone injections based on change in tumor volume at 2 years and 2 more. Started Jun 2018; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
desmoid tumor
Beyond the preview
Go deeper on NCT03627741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627741.